Recent News Releases

Feb 12, 2019

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to...

Feb 5, 2019

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and...

Jan 11, 2019

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to...

Jan 3, 2019

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX : IN) (OTCQX : IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and...

See All News Releases

Letter to Shareholders

Annual Letter to Shareholders 2019

January 31, 2019

Download pdf

Company Fact Sheet

Company Fact Sheet

January 2, 2019

Download pdf

SEDAR® Filings
Loading data...
Financial Reports

Quarterly and Annual Financial Results

2019

Second quarter, 2019 (quarter ended December 31, 2018)
First quarter, 2019 (quarter ended September 30, 2018)

2018

AGM Documents
Fourth quarter, 2018 (full year ended June 30, 2018)
Third quarter, 2018 (quarter ended March 31, 2018)
Second quarter, 2018 (quarter ended December 31, 2017)
First quarter, 2018 (quarter ended September 30, 2017)

2017

Fourth quarter, 2017 (full year ended June 30, 2017)
Third quarter, 2017 (quarter ended March 31, 2017)
Second quarter, 2017 (quarter ended December 31, 2016)
First quarter, 2017 (quarter ended September 30, 2016)

Stock Performance

-
Loading...
Display Events
 
 
 
 
Chart Style
Analyst Coverage
Firm Analyst E-mail Phone
Edison Investment Research Maxim Jacobs MJacobs@edisongroup.com +1 (646) 653-7027